Caribou Biosciences (NASDAQ:CRBU) and Titan Pharmaceuticals (NASDAQ:TTNP) Financial Comparison

Titan Pharmaceuticals (NASDAQ:TTNP) and Caribou Biosciences (NASDAQ:CRBU) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk and analyst recommendations.

Risk and Volatility

Titan Pharmaceuticals has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Comparatively, Caribou Biosciences has a beta of 2.27, meaning that its stock price is 127% more volatile than the S&P 500.

Profitability

This table compares Titan Pharmaceuticals and Caribou Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Titan Pharmaceuticals	N/A	-87.90%	-75.11%
Caribou Biosciences	-372.78%	-34.76%	-29.58%

Earnings & Valuation

This table compares Titan Pharmaceuticals and Caribou Biosciences”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Titan Pharmaceuticals	$180,000.00	20.26	-$5.57 million	N/A	N/A
Caribou Biosciences	$33.11 million	5.35	-$102.07 million	($1.39)	-1.41

Titan Pharmaceuticals has higher earnings, but lower revenue than Caribou Biosciences.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Titan Pharmaceuticals and Caribou Biosciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Titan Pharmaceuticals	0	0	0	0	N/A
Caribou Biosciences	0	1	3	0	2.75

Caribou Biosciences has a consensus target price of $11.25, indicating a potential upside of 473.98%. Given Caribou Biosciences’ higher possible upside, analysts plainly believe Caribou Biosciences is more favorable than Titan Pharmaceuticals.

Institutional & Insider Ownership

31.5% of Titan Pharmaceuticals shares are held by institutional investors. Comparatively, 77.5% of Caribou Biosciences shares are held by institutional investors. 24.9% of Titan Pharmaceuticals shares are held by insiders. Comparatively, 9.5% of Caribou Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Caribou Biosciences beats Titan Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder. The company was founded in 1991 and is based in South San Francisco, California.

About Caribou Biosciences

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.